

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – December 12, 2012 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. November 14, 2012 DUR Minutes – Vote
 - B. November 15, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Medication Coverage Activity for November 2012
 - B. Pharmacy Help Desk Activity for November 2012
 - C. SoonerCare Atypical Rx Program Update

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Rayos[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Relistor[®] – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

7. **Drug Utilization Review of Chronic Obstructive Pulmonary Disease Medications – See Appendix E.**
 - A. Introduction
 - B. Treatment
 - C. Clinical Comparison
 - D. Utilization Trends
 - E. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Amitiza[®] and 30 Day Notice to Prior Authorize Linzess[™] – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Smoking Cessation Products – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix H.**

11. **Future Business**
 - A. Annual Reviews
 - B. New Product Reviews
 - C. Safety Alerts

12. **Adjournment**